Depression of the N-demethylation of erythromycin, azithromycin, clarithromycin and clindamycin in murine Toxoplasma infection

International Journal for Parasitology

Volumn 26, Issue 11, 1996, Pages 1321-1323

  Berg Candolfi, Martine ^a   Candolfi, Ermanno ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

azithromycin; clarithromycin; clindamycin; cytochrome P450 3A; erythromycin; intestine; liver; mouse; N demet hylation; Toxoplasma infection

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; CLINDAMYCIN; CYTOCHROME P450; ERYTHROMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG ACTIVITY; DRUG METABOLISM; INTESTINE; LIVER; MOUSE; NONHUMAN; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; AZITHROMYCIN; CLARITHROMYCIN; CLINDAMYCIN; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ERYTHROMYCIN; INTESTINAL MUCOSA; JEJUNUM; KINETICS; MICE; MICROSOMES; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; REFERENCE VALUES; TIME FACTORS; TOXOPLASMOSIS, ANIMAL;

ANIMALIA; MURINAE; STAPHYLOCOCCUS PHAGE 3A; TOXOPLASMA; TOXOPLASMA GONDII;

EID: 0030295005     PISSN: 00207519     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7519(96)00111-7     Document Type: Article

References (22)

1. Araujo F. G. & Remington J. S. 1974. Effect of clindamycin on acute and chronic toxoplasmosis in mice. Antimicrobial Agents and Chemotherapy 5: 647-651.
2. Araujo F. G. & Remington J. S. 1992. Recent advances in the search for new drugs for treatment of toxoplasmosis. International Journal of Antimicrobial Agents 1: 153-164.
3. Araujo F. G., Prokocimer P. & Remington J. S. 1993. Activity of clarithromycin in murine models of toxoplasmosis. Journal of Chemotherapy 5: 519-520.
4. Araujo F. G., Shepard R. M. & Remington J. S. 1991. In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii. European Journal of Clinical Microbiology and Infectious Diseases 10: 519-524.
5. Araujo F. G., Prokocimer P., Lin T. & Remington J. S. 1992. Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis. Antimicrobial Agents & Chemotherapy 36: 2454-2457.
6. G-monomethyl-L-arginine on the hepatic suppression. Xenobiotica 26: 381-394.
7. Black J. R. & Remington J. S. 1992. Clindamycin in the treatment of Pneumocystis carinii pneumonia and Toxoplasma gondii encephalitis in patients infected with HIV. In: Clindamycin in the Treatment of Human Infections (Edited by Zambrano D.), pp. 13-33. The Upjohn Co., Kalamazoo, MI.
8. Bradford M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72: 248-254.
9. Candolfi E., Hunter C. A. & Remington J. S. 1994. Mitogen and antigen specific proliferation of T cells in murine toxoplasmosis is inhibited by reactive nitrogen intermediates. Infection and Immunity 62: 1995-2001.
10. Dannemann B. R., Israelski D. M. & Remington J. S. 1988. Treatment of toxoplasmic encephalitis with intravenous clindamycin. Archives of International Medicine 148: 2477-2482.
11. Dannemann B. R., McCutchan J. A., Israelski D. M., Antoniskis D., Leport C., Luft B., Nussbaum J., Clumeck N., Morlat P., Chiu J., Vilde J. L., Orellana M., Feigal D., Bartok A., Heseltine P., Leedom J. & Remington J. S. The California Treatment Group. 1992. Treatment of toxoplasmic encephalitis in patients with AIDS: a randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Annals of International Medicine 116: 33-43.
12. Fernandez-Martin J., Leport C., Morlat P., Meyohas M. C., Chauvin J. P. & Vilde J. L. 1991. Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. Antimicrobial Agents and Chemotherapy 35: 2049-2052.
13. Ferrero J. L., Bopp B. A., Marsh K. C., Quigley S. C., Johnson M. J., Anderson D. J., Lamm J. E., Tolman K. G., Sanders S. W., Cavanaugh J. H. & Sonders R. C. 1990. Metabolism and disposition of clarithromycin in man. Drug Metabolism and Disposition 18: 441-446.
14. Fraschini F., Scaglione F. & Demartini G. 1993. Clarithromycin clinical pharmacokinetics. Clinical Pharmacokinetics 25: 189-204.
15. Hofflin J. M. & Remington J. S. 1986. Clindamycin in a murine model of toxoplasmic encephalitis. Antimicrobial Agents and Chemotherapy 31: 492-496.
16. Kanatani M. S. & Guglielmo B. J. 1994. The new macrolides azithromycin and clarithromycin. Western Journal of Medicine 160: 31-37.
17. Lacassin F., Schaffo D., Perronne C., Longuet P., Leport C. & Vilde J. L. 1995. Clarithromycin-minocycline combination as salvage therapy for toxoplasmosis in patients infected with human immunodeficiency virus. Antimicrobial Agents and Chemotherapy 39: 276-277.
18. Nash T. 1953. The colorimetric estimation of formaldehyde by means of the Hantzsch reaction. Biochemical Journal 55: 416-421.
19. Peters D. H., Friedel H. A. & McTavish D. 1992. Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 44: 750-799.
20. Sande M. A. & Mandell G. L. 1993. Antimicrobial agents: tetracyclines, chloramphenicol, erythromycin, and miscellaneous antibacterial agents. In: The Pharmacological Basis of Therapeutics (Edited by Goodman Gilman A.), pp. 1117-1145. Pergamon Press, New York.
21. Schentag J. J. & Ballow C. H. 1991. Tissue-directed pharmacokinetics. American Journal of Medicine 91: 5S-11S.
22. Watkins P. B., Wrighton S. A., Maurel P., Schuetz E. G., Mendez-Picon G., Parker G. A. & Guzelian P. S. 1985. Identification of an inducible form of cytochrome P-450 in human liver. Proceedings of the National Academy of Sciences U.S.A. 82: 6310-6314.